Rinascera Therapeutics, Inc. — Form D
Rinascera Therapeutics, Inc. of BOSTON, MA, a company, filed a Form D exempt-offering notice with the SEC on 2025-10-08. The offering totals $2.5M, of which $2.5M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2025-10-08
- Form: D
- Accession: 0002090779-25-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $2.5M
- Amount sold: $2.5M
- Investors: 3
- Date of first sale: 2025-09-12
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-560207
Issuer
- Name: Rinascera Therapeutics, Inc.
- CIK: 0002090779
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2025
- Address: 75 KNEELAND ST FL 14, BOSTON, MA, 02111
- Phone: (408) 396-3123
Officers, directors & promoters (6)
| Name | Role | Location |
|---|
| Karl Beutner | Director | BOSTON, MA |
| Nichola Eliovits | Director | Austin, TX |
| Daniel Yadegar | Director | BOSTON, MA |
| Karl Beutner | Executive Officer | BOSTON, MA |
| Max Dawson | Executive Officer | BOSTON, MA |
| Nichola Eliovits | Executive Officer | Austin, TX |
More